Nutritional Strategy for Glycemic Control in Patients With Type 2 Diabetes Mellitus (NUGLIC)
Effectiveness of a Nutritional Strategy for Glycemic Control in Patients With Type 2 Diabetes Mellitus Users of a Public Health System: NUGLIC Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Governador Valadares, Brazil
- Universidade Federal de Juiz de Fora
-
Lavras, Brazil
- Universidade Federal de Lavras
-
Porto Alegre, Brazil
- Hospital de Clínicas de Porto Alegre - Universidade Federal do Rio Grande do Sul
-
Porto Alegre, Brazil
- Universidade Federal de Ciências da Saúde de Porto Alegre
-
Rio De Janeiro, Brazil
- Instituto Estadual de Cardiologia Aloysio de Castro
-
Salvador, Brazil
- Universidade Federal da Bahia
-
São Paulo, Brazil, 04004-030
- Hospital do Coracao
-
Viçosa, Brazil
- Universidade Federal de Viçosa
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: >30 years old with medical diagnosis of T2DM, glycated hemoglobin (HbA1C) ≥7% at the moment of the screening and who have not received or received nutritional counseling for at least 06 months.
Exclusion Criteria:
- Patients with type 1 DM (T1DM), latent autoimmune diabetes in adults (LADA) or HbA1C ≥ 12%;
- Severe neuropathy;
- Chronic kidney disease;
- Active cancer or life expectancy <6 months;
- Chemical dependence or use of antipsychotic drugs;
- Autoimmune disease or chronic use of steroids;
- Gastroparesis;
- Pregnancy, lactation, gestational DM;
- Acute coronary syndrome (ACS) in the last 60 days;
- Wheelchair users;
- Extreme obesity (body mass index [BMI] ≥40kg/m²);
- Cognitive, neurological or psychiatric condition that prevents participation in the study;
- Participation in other clinical trials.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Nutritional Strategy
Nutritional counseling based on the quality of the diet, the Food Guide for the Brazilian Population and concepts of mindfulness and mindful eating; dietary guidance based on feasible goals built together (patient and nutritionist).
|
Counseling based on dietary goals and mindfulness techniques.
|
|
Active Comparator: Dietary Prescription
Individualized dietary prescription according to the guidelines of the Brazilian Society of Diabetes.
|
Dietary prescription according to guidelines.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HbA1C
Time Frame: 6 months
|
Glycated hemoglobin, in %
|
6 months
|
|
GC
Time Frame: 6 months
|
Glycemic control, defined as either having HbA1C > 7% at baseline and achieving HbA1C ≤ 7% after follow-up or having HbA1C < 7% at baseline and reducing anti-diabetic drugs after follow-up.
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
FG
Time Frame: 6 months
|
Fasting glucose, in mg/dL
|
6 months
|
|
SBP
Time Frame: 6 months
|
Systolic blood pressure, in mmHg
|
6 months
|
|
DBP
Time Frame: 6 months
|
Diastolic blood pressure, in mmHg
|
6 months
|
|
HDL-c
Time Frame: 6 months
|
HDL cholesterol, in mg/dL
|
6 months
|
|
LDL-c
Time Frame: 6 months
|
LDL cholesterol, in mg/dL; it will be obtained by the Martin´s mathematical formula
|
6 months
|
|
TC
Time Frame: 6 months
|
Total cholesterol, in md/dL
|
6 months
|
|
TG
Time Frame: 6 months
|
Serum triglycerides, in mg/dL
|
6 months
|
|
Castelli Index I
Time Frame: 6 months
|
Castelli Index I, obtained by the mathematical formula TC/HDL-c
|
6 months
|
|
VLDL-c
Time Frame: 6 months
|
VLDL cholesterol, in mg/dL; it will be obtained by the mathematical formula TG/5
|
6 months
|
|
NHDL
Time Frame: 6 months
|
Non-HDL cholesterol, in mg/dL; it will be obtained by the mathematical formula TC - HDL-c
|
6 months
|
|
Castelli Index II
Time Frame: 6 months
|
Castelli Index II, obtained by the mathematical formula LDL-c/HDL-c
|
6 months
|
|
BW
Time Frame: 6 months
|
Body weight, in kg
|
6 months
|
|
WC
Time Frame: 6 months
|
Waist circumference, in cm
|
6 months
|
|
BMI
Time Frame: 6 months
|
Body mass index, in kg/m2; it will be obtained by the mathematical formula (BW/height*height)
|
6 months
|
|
Cr
Time Frame: 6 months
|
Creatinine, in mg/dL
|
6 months
|
|
GFR
Time Frame: 6 months
|
Glomerular filtration rate, in ml/min/1.73m2
|
6 months
|
|
Sodium (s)
Time Frame: 6 months
|
Serum sodium, in mEq/L
|
6 months
|
|
Sodium (u)
Time Frame: 6 months
|
Urinary sodium, in mEq/L
|
6 months
|
|
Potassium (s)
Time Frame: 6 months
|
Serum potassium, in mEq/L
|
6 months
|
|
Potassium (u)
Time Frame: 6 months
|
Urinary potassium, in mEq/L
|
6 months
|
|
ALB
Time Frame: 6 months
|
Albuminuria, in mg/g
|
6 months
|
|
B-PAID
Time Frame: 6 months
|
Quality of life evaluated by the Brazilian version of the Problem Areas in Diabetes Scale.
The scale consists of 20 questions; it uses a score from 0 to 100, in which the maximum score is configured as greater suffering.
The possible response options are divided on a 5-point Likert scale, ranging from: "Not a problem=0", "Small problem=1", "Moderate problem=2", "Almost serious problem=3", "Serious problem=4".
A cut-off point equal or greater 40 indicates a high degree of emotional distress.
|
6 months
|
|
DSCA
Time Frame: 6 months
|
Self-care evaluated by the Brazilian version of the Diabetes Self-Care Activities.
The questionnaire has six domains and 15 items for assessment of the diabetes self-care; it is based on the number of days per week in which the respondent has a given behavior, with each item scoring from 0 to 7 points (i.e.
0 is the least desirable situation and 7 is the most desirable one).
At least five days for each self-care activity is considered adequate.
|
6 months
|
|
DQ
Time Frame: 6 months
|
Diet quality, evaluated by the modified Alternative Healthy Eating Index (mAHEI)
|
6 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
TT
Time Frame: 6 months
|
Therapeutic targets, defined as the proportion of participants who reached the following therapeutic targets: SBP/DBP < 130/80 mmHg; HbA1C <7%; LDL-c <100 mg/dL; BMI < 25 kg/m2 or weight loss > 7%
|
6 months
|
|
ADD
Time Frame: 6 months
|
Anti-diabetic drugs, defined as the type and proportion of anti-diabetic drugs used
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Aline Marcadenti, PhD, Hospital do Coracao
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NUGLIC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.